Antibiotic resistance is a perfect storm. The overuse and misuse of antibiotics is accelerating the pace at which bacteria are developing resistance to treatments. Meanwhile, pharmaceutical companies are leaving the market or even going bankrupt, and the remaining companies are not developing sufficiently innovative solutions for difficult-to-treat infections. And even antibiotics that have been developed are not reaching regions of the world that need them most. GARDP seeks to discover and develop antibiotics for the most difficult-to-treat infections and make them accessible to people everywhere.
5 new treatments by 2025 and beyond
GARDP’s “5 by 25” initiative aims to deliver five new treatments by 2025.
Targeting key disease areas
GARDP focuses on bringing better solutions in two disease areas that have been greatly impacted by antibiotic resistance: serious bacterial infections that could lead to sepsis and death, with a special focus on children and newborn babies; sexually transmitted infections such as gonorrhoea.
Addressing the most urgent threats to public health
1 in 5 deaths caused by drug-resistant infections occur in children under the age of five, and up to 3 million newborns get serious infections that lead to sepsis every year.
Serious Bacterial Infections
Serious bacterial infections are among the major causes of death for people in hospitals and other healthcare settings.
Sexually Transmitted Infections
Gonorrhoea affects 82 million people each year, and disproportionately harms women. Resistant strains are spreading around the world.
Discovery & Exploratory Research
Growing drug resistance is outpacing the development of antibiotics for the most difficult-to-treat infections. Producing such antibiotics starts with the earliest stage of drug development.
Access to Antibiotics
Lack of access to novel antibiotics is a global problem that acutely affects whole countries and regions as well as certain population groups like children.
GARDP develops treatments for the most harmful and deadly bacteria
A recent study found that just six pathogens—all of which are recognized as priority pathogens in need of new treatments by the World Health Organization (WHO)—are responsible for the majority of the nearly 1.3 million deaths caused by antibiotic resistance each year. GARDP is developing and making accessible new treatments for these pathogens.
GARDP works to stop the spread of drug-resistant infections
Antibiotic resistance knows no boundaries. Resistance mechanisms are passed on by multiplying bacteria and are spread among neighbouring bacteria. To stop the spread of drug-resistant infections, GARDP is investing in new treatments and expanded access to antibiotics, including SECURE, a collaborative initiative to accelerate access to a portfolio of essential antibiotics in order to help countries prepare for and respond to a pandemic of drug-resistant infections.
GARDP contributes to global efforts for sustainable development
At the heart of the 2030 Agenda for Sustainable Development are 17 Sustainable Development Goals (SDGs) which aim to create peace and prosperity for all people and the planet. GARDP contributes to SDG 3—ensure healthy lives and promote well-being for all at all ages. Since bacterial resistance can affect anyone anywhere, everyone stands to benefit from effective and accessible treatments.
In addition, GARDP contributes to SDG 5—gender equality and women’s empowerment, and especially to universal access to sexual and reproductive health—via its treatment for gonorrhoea, since women suffer disproportionately from this sexually transmitted infection.